Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas

Posted on by admin

REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitorsSalt Lake City, UT, April 08, 2025 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient has […]

Read More

Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer

Posted on by admin

SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025. A strategic, results-oriented leader with more than 20 years of experience in healthcare, diagnostics, and medical […]

Read More

Merit Medical Launches the Ventrax™ Delivery System

Posted on by admin

Novel all-in-one retrograde aortic access delivery system supports streamlined treatment of ventricular tachycardia SOUTH JORDAN, Utah, April 09, 2025 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced the US commercial release of its Ventrax Delivery System. The new delivery system is Merit’s latest addition to its growing […]

Read More

PhotoPharmics Reaches 200 Participants in Landmark Light for PD Clinical Trial

Posted on by admin

Two-thirds enrolled in one of the largest remote Parkinson’s trials—redefining access and inclusion in therapeutic research Salt Lake City, Utah – PhotoPharmics announced today that its Pivotal, Phase 3 clinical trial, Light for PD™, has now reached 200 participants—marking two-thirds of its target enrollment. This milestone positions the study as one of the largest remote […]

Read More

Ribbon Cutting Ceremony for New Denali Facility in Salt Lake City

Posted on by admin

BioUtah member, Denali Therapeutics, yesterday celebrated the grand opening of its new state-of-the-art manufacturing facility in Salt Lake City. Denali is using deep scientific and drug development expertise to discover and deliver effective biologic therapeutics to the brain. Co-founder and CEO, Ryan Watts, addressed the crowd who gathered to share the milestone with colleagues, public […]

Read More

bioMérieux receives FDA 510(k) Clearance for its VITEK® COMPACT PRO

Posted on by admin

Marcy l’Étoile, France, March 18th, 2025 – bioMérieux, a world leader in the field of in vitro diagnostics, announces the U.S. Food and Drug Administration (FDA) 510(k) clearance for VITEK® COMPACT PRO. This innovative system for microorganism identification (ID) and antibiotic susceptibility testing (AST) will benefit clinical laboratories to help diagnose infectious diseases and combat […]

Read More

Halia Therapeutics Awarded Novo Nordisk Golden Ticket to Advance Obesity and Inflammation Research

Posted on by admin

Fully Sponsored BioLabs Lab Space to Support Halia’s Next Phase of Development LEHI, Utah, Feb. 25, 2025 /PRNewswire/ – Halia Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for chronic inflammation and obesity-related diseases, announced today that it has been awarded the Novo Nordisk Golden Ticket. This prestigious award provides Halia with a fully sponsored […]

Read More